Last reviewed · How we verify
Gramoderm (GRAMICIDIN)
Gramoderm (Gramicidin) is a small molecule antibiotic developed by Monarch Pharms, targeting thromboxane-A synthase. It is used to treat various bacterial infections of the eye, including conjunctivitis, keratitis, and blepharitis. Gramoderm was FDA-approved in 1968 and remains a proprietary product of Monarch Pharms. Key safety considerations include its potential for ocular irritation and allergic reactions. As a gramicidin antibiotic, Gramoderm works by disrupting bacterial cell membranes.
At a glance
| Generic name | GRAMICIDIN |
|---|---|
| Sponsor | Pfizer |
| Drug class | gramicidin |
| Target | Thromboxane-A synthase |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1968 |
Approved indications
- Bacterial conjunctivitis
- Bacterial keratitis
- Blepharoconjunctivitis
- Infective blepharitis
- Superficial Ocular Infection
Common side effects
- allergic reactions
- itching
- swelling
- conjunctival erythema
- anaphylaxis
- local irritation
Key clinical trials
- Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers (PHASE1)
- Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges (PHASE2)
- Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers (PHASE1)
- Phage Therapy for the Prevention and Treatment of Wound Infections in Burned Patients (PHASE1)
- Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers (NA)
- Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections (NA)
- Comparison Between Bandage Contact Lens and Pressure Patching for The Erosion Area and Pain Scale in Corneal Erosion Patients (PHASE3)
- A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gramoderm CI brief — competitive landscape report
- Gramoderm updates RSS · CI watch RSS
- Pfizer portfolio CI